• Zelluna’s annual report outlines progress toward first-in-human testing of its TCR-NK platform, with the lead program ZI-MA4-1 advancing through GMP manufacturing and clinical trial preparations.
• The company submitted a UK clinical trial application for ZI-MA4-1 in December 2025, which was later approved in February 2026.
• It entered a clinical partnership with Medpace in February 2026 to support the Phase 1 ZIMA-101 trial in advanced solid cancers, with initial clinical data expected from mid-2026.
• In FY2025, total operating expenses rose to NOK 144 million and loss widened to NOK 141 million.
• Zelluna ended FY2025 with NOK 78 million in cash and cash equivalents, up due to two private placements and cash acquired through the business combination completed in March 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.